1. Scrip

Sickle Cell Disease Market Snapshot: "The Time Has Come"

 
• By Jessica Merrill

Three new drugs for sickle cell disease could be on the market in the US next year, representing a groundswell of advancement for the devastating blood disorder that has had limited options.

Hand flip wooden cube with word change to chance, Personal development and career growth or change yourself concept - Image
Big changes are in store for the sickle cell disease treatment market • Source: Shutterstock

With one new drug on the market in the US and two more pending at the US Food and Drug Administration, 2020 is positioned to be a turning point for the treatment of sickle cell disease. Patients with the devastating blood disorder, which results in acute pain crises, long-term organ damage and a shortened lifespan, have had few treatment options, but the outlook for sickle cell R&D is brighter than it has been.

"The time has come. We are at the cusp of improving the quality of life for people with sickle cell disease," said hematologist Charles Abrams, director of the blood center for patient care and discovery at the University of Pennsylvania and Children's Hospital of Philadelphia

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Market Snapshot

More from Scrip

Executives On The Move: Altesa BioSciences Acquires Chief Medical Officer From GSK, Scholar Rock Gets A New CEO, And More

Recent moves in the industry include C-suite changes at Scholar Rock and Augustine Therapeutics, plus Contineum Therapeutics acquires chief medical officer from Gilead Sciences.

Dr Reddy’s Gears For Tariffs Scenario, To Ensure No US Supply Disruption

 
• By Anju Ghangurde

Dr. Reddy's Laboratories preps for potential US tariffs, focusing on sustaining product supply and collaborating with customers on inventories. A recent US plant sale, the firm stressed, was unrelated to tariffs and underlines its openness to ‘make in the US’, where it launched 18 products in fiscal 2025.

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's episode: industry makes its case to Trump; Sarepta slammed by double blow; Chinese firms build obesity pipeline; Swiss biopharma staying strong; and Merck & Co looks to immunology and ophthalmology.